HIGHLIGHTS
- who: Rehab H. Werida from the Faculty of Pharmacy have published the Article: Role of alpha-lipoic acid in counteracting paclitaxel- and doxorubicin-induced toxicities: a randomized controlled trial in breast cancer patients, in the Journal: (JOURNAL)
- what: The dose of alpha-lipoic_acid used during this study (600 mg daily) was selected depending up-on some previous studies and demonstrated that an oral dose of 600 mg alpha-lipoic_acid daily improved neuropathic symptoms in diabetic patients with polyneuropathy and provided cardio-protective effect with subsequent improvement of subclinical left ventricular dysfunction in asymptomatic patients with . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.